JP2005530723A - 新規ペプチド及び治療を目的とするその利用 - Google Patents

新規ペプチド及び治療を目的とするその利用 Download PDF

Info

Publication number
JP2005530723A
JP2005530723A JP2003582175A JP2003582175A JP2005530723A JP 2005530723 A JP2005530723 A JP 2005530723A JP 2003582175 A JP2003582175 A JP 2003582175A JP 2003582175 A JP2003582175 A JP 2003582175A JP 2005530723 A JP2005530723 A JP 2005530723A
Authority
JP
Japan
Prior art keywords
peptide
cytokine
amino acids
cytokines
ifnα
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003582175A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005530723A5 (enExample
Inventor
ザグリ，ジャン−フランソワ
Original Assignee
バクスコンスュルタン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バクスコンスュルタン filed Critical バクスコンスュルタン
Publication of JP2005530723A publication Critical patent/JP2005530723A/ja
Publication of JP2005530723A5 publication Critical patent/JP2005530723A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5409—IL-5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5437—IL-13
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2003582175A 2002-04-10 2003-04-09 新規ペプチド及び治療を目的とするその利用 Pending JP2005530723A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0204464A FR2838444B1 (fr) 2002-04-10 2002-04-10 Nouveaux peptides et leur application en therapeutique
PCT/FR2003/001120 WO2003084979A2 (fr) 2002-04-10 2003-04-09 Peptides et leur application en therapeutique

Publications (2)

Publication Number Publication Date
JP2005530723A true JP2005530723A (ja) 2005-10-13
JP2005530723A5 JP2005530723A5 (enExample) 2006-05-25

Family

ID=28459716

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003582175A Pending JP2005530723A (ja) 2002-04-10 2003-04-09 新規ペプチド及び治療を目的とするその利用

Country Status (20)

Country Link
US (6) US7393523B2 (enExample)
EP (3) EP1492814B1 (enExample)
JP (1) JP2005530723A (enExample)
KR (1) KR101101004B1 (enExample)
CN (1) CN1649898A (enExample)
AT (1) ATE526985T1 (enExample)
AU (1) AU2003260031B2 (enExample)
CA (1) CA2480996C (enExample)
DK (1) DK2314311T3 (enExample)
ES (2) ES2550030T3 (enExample)
FR (1) FR2838444B1 (enExample)
IL (1) IL164429A0 (enExample)
MA (1) MA27191A1 (enExample)
MX (1) MXPA04009841A (enExample)
NZ (1) NZ536351A (enExample)
RU (1) RU2326125C2 (enExample)
SI (1) SI2314311T1 (enExample)
TN (1) TNSN04200A1 (enExample)
WO (1) WO2003084979A2 (enExample)
ZA (1) ZA200408451B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018521016A (ja) * 2015-06-03 2018-08-02 アフィリス・アクチェンゲゼルシャフトＡｆｆｉｒｉｓ Ａｇ ＩＬ−２３−ｐ１９ワクチン

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7422743B2 (en) * 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
FR2859725B1 (fr) * 2003-09-16 2006-03-10 Neovacs Procede a haut rendement pour l'obtention d'anticorps humains neutralisant l'activite biologique d'une cytokine humaine
MXPA06009805A (es) 2004-02-27 2007-04-02 Vaxconsulting Peptidos de interleucina 1 beta y factor de necrosis tumoral alfa y metodo de tratamiento utilizando los mismos.
JP5312028B2 (ja) 2005-09-28 2013-10-09 サイトス バイオテクノロジー アーゲー インターロイキン−１コンジュゲート及びその使用
CN102216323B (zh) * 2008-11-17 2016-08-03 哥本哈根大学 用于调节慢性炎症反应和治疗自身免疫性疾病的源自il-4的肽
EP2480251B1 (en) 2009-09-21 2025-12-03 Peptinov Carrier conjugates of il-23-peptides and their induced antibodies
EP2569326B1 (en) 2010-05-11 2016-08-10 The U.S.A. as represented by the Secretary, Department of Health and Human Services Peptide-based inhibitor of interleukin-10 or stat-3 activation
IN2014MN02060A (enExample) * 2012-03-18 2015-08-21 Univ Kyushu Nat Univ Corp
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
EP4614154A3 (en) * 2017-10-13 2025-11-26 Nibec Co., Ltd. Grp78-derived peptide for identifying high-efficiency stem cells
AU2020275076A1 (en) * 2019-05-10 2021-11-25 Bimyo GmbH BNIP3 peptides for treatment of reperfusion injury
AU2023223603A1 (en) 2022-02-28 2024-08-22 Tridem Bioscience Gmbh & Co Kg A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN.

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772685A (en) * 1985-10-02 1988-09-20 Merck & Co., Inc. Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies
US5013824A (en) * 1985-11-19 1991-05-07 Schering Corporation Human interleukin-4 peptides and conjugates thereof
DE3841761A1 (de) * 1988-12-12 1990-06-13 Basf Ag Neue tnf-peptide
DE69026627T2 (de) * 1989-12-20 1996-08-22 Schering Corp., Kenilworth, N.J. Antikörperantagonisten gegen humanes interleukin-4
WO1991014702A1 (en) * 1990-03-19 1991-10-03 Peptide Technology Ltd. Anti-tumour peptides
FR2677654B1 (fr) * 1991-06-17 1995-11-17 Pasteur Merieux Serums Vacc Composes a effet immunogene anti-cytokine, a effet immunogene anticytostatique ou a effet vaccinal anti-infection a hiv.
US6117974A (en) * 1991-10-02 2000-09-12 Peptor Limited Libraries of backbone-cyclized peptidomimetics
US5494662A (en) * 1992-04-27 1996-02-27 Ono Pharmaceutical Co., Ltd. Stimulator for bone formation
CA2139571C (en) * 1992-07-07 2006-11-14 Eleanor N. Fish Interferon receptor binding peptides
US5770191A (en) * 1995-05-24 1998-06-23 University Of Florida Active C-terminal peptides of interferon--gamma and their use
US5994292A (en) * 1995-05-31 1999-11-30 The United States Of America As Represented By The Department Of Health And Human Services Interferon-inducible protein 10 is a potent inhibitor of angiogenesis
IT1277926B1 (it) * 1995-09-01 1997-11-12 Angeletti P Ist Richerche Bio Uso di muteine di citochine naturali come immunogeni per la preparazione di composizioni farmaceutiche per curare o prevenire
US6346602B1 (en) * 1997-02-07 2002-02-12 Thomas Jefferson University Peptide mimics of the cytokine receptor common γ chain and methods and compositions for making and using the same
IT1291353B1 (it) * 1997-05-12 1999-01-07 San Raffaele Centro Fond Peptidi con attivita' antivirale
WO1999050416A1 (en) * 1997-09-30 1999-10-07 Pharmacia & Upjohn Company Tnf-related death ligand
WO2000047620A1 (en) * 1999-02-08 2000-08-17 Medvet Science Pty Ltd Cytokine-binding domain
KR20010102556A (ko) * 1999-03-11 2001-11-15 추후제출 암 및 과증식성 장애의 치료 조성물 및 치료방법
US7129072B1 (en) * 1999-08-30 2006-10-31 New York University Crystal of fibroblast growth factor receptor 1 in complex with fibroblast growth factor
US6420346B1 (en) * 2000-02-07 2002-07-16 Rappaport Family Institute For Research In The Medical Sciences Polynucleotides encoding MIP-1α, MCP-1, MIP-1β, Rantes and TNF-α, and methods for treating rheumatoid arthritis
WO2002044197A2 (en) * 2000-12-01 2002-06-06 Fish Eleanor N Cytokine receptor binding peptides
US20030166589A1 (en) * 2001-06-05 2003-09-04 Nathan Karin Method and pharmaceutical composition for the treatment of multiple sclerosis

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018521016A (ja) * 2015-06-03 2018-08-02 アフィリス・アクチェンゲゼルシャフトＡｆｆｉｒｉｓ Ａｇ ＩＬ−２３−ｐ１９ワクチン

Also Published As

Publication number Publication date
FR2838444B1 (fr) 2016-01-01
ZA200408451B (en) 2006-01-25
US20120121627A1 (en) 2012-05-17
DK2314311T3 (en) 2015-10-12
MXPA04009841A (es) 2005-06-17
ES2550030T3 (es) 2015-11-04
RU2326125C2 (ru) 2008-06-10
CA2480996C (fr) 2016-06-21
US8529881B2 (en) 2013-09-10
WO2003084979A2 (fr) 2003-10-16
US8277792B2 (en) 2012-10-02
EP2314312A2 (fr) 2011-04-27
US7892529B2 (en) 2011-02-22
ES2375053T3 (es) 2012-02-24
TNSN04200A1 (fr) 2007-03-12
KR101101004B1 (ko) 2011-12-29
EP2314311A2 (fr) 2011-04-27
WO2003084979A3 (fr) 2004-04-08
KR20040108709A (ko) 2004-12-24
US20080260689A1 (en) 2008-10-23
AU2003260031B2 (en) 2009-10-29
US20120321652A1 (en) 2012-12-20
US8147819B2 (en) 2012-04-03
US20110171169A1 (en) 2011-07-14
IL164429A0 (en) 2005-12-18
US7641895B2 (en) 2010-01-05
ATE526985T1 (de) 2011-10-15
AU2003260031A1 (en) 2003-10-20
EP2314311A3 (fr) 2011-08-17
EP1492814B1 (fr) 2011-10-05
SI2314311T1 (sl) 2015-12-31
NZ536351A (en) 2007-03-30
EP2314311B1 (fr) 2015-07-15
CN1649898A (zh) 2005-08-03
US20100150957A1 (en) 2010-06-17
RU2004132871A (ru) 2005-09-20
US7393523B2 (en) 2008-07-01
EP1492814A2 (fr) 2005-01-05
FR2838444A1 (fr) 2003-10-17
US20060241286A1 (en) 2006-10-26
EP2314312A3 (fr) 2011-08-31
CA2480996A1 (fr) 2003-10-16
MA27191A1 (fr) 2005-01-03

Similar Documents

Publication Publication Date Title
US7892529B2 (en) Peptides for active anti-cytokine immunization
US8632781B2 (en) Immunogenic compounds comprising peptides of IL1β
US20030194391A1 (en) Vaccine
AU2002233560A1 (en) Vaccine
CN113226348B (zh) 免疫治疗il-6失调疾病的il-6的肽免疫原及其制剂
AU2011213784A1 (en) Peptides of IL1 BETA and TNF and method of treatment using same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060329

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060329

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090310

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090609

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090616

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090910

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091013